Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01896934 · ClinicalTrials.gov registry record · Phase 4
Frontal Hypoperfusion Effects on Antidepressant Outcomes in Late-Life Depression
A Phase 4 study of Major Depressive Disorder, sponsored by Vanderbilt University.
- Completed
- Registry status
- Phase 4
- Development phase
- 31
- Enrollment target
- 1
- Study location
NCT01896934 is a Phase 4 study of Major Depressive Disorder that has completed, run by Vanderbilt University. The registered enrollment target is 31 participants, below the 377-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01896934, a Phase 4 study of Major Depressive Disorder, has completed, sponsored by Vanderbilt University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 31 participants
- Enrollment target
- 1
- Study location
Study Summary
The long-term goal of this line of research is to determine if decreased vascular reactivity and frontal hypoperfusion is associated with poor response antidepressants. Such perfusion deficits could contribute to antidepressant nonresponse as they would hinder improvements in dorsal system metabolism seen with antidepressant treatment. The objective of the current proposal is to determine if decreased vascular reactivity and frontal hypoperfusion in depressed elders predicts and persists with antidepressant nonremission. The investigators will pursue the primary aim testing the hypothesis that decreased reactivity and hypoperfusion, specifically in the dorsolateral prefrontal cortex and dorsal anterior cingulate cortex, predict antidepressant nonremission. The investigators will enroll 40 depressed elders who will complete clinical, cognitive, and MRI assessments before and after a 12-week open-label antidepressant trial of sertraline.
Conditions Studied
Interventions
- DRUG Sertraline
Study Locations (1)
Tennessee
- Vanderbilt University - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2013-07 |
| Est. Completion | 2016-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01896934
The ClinicalTrials.gov registry entry for NCT01896934 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 377-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (92% lower). The listed sponsor is Vanderbilt University, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Major Depressive Disorder appearing as the primary indexed condition, and to 1 intervention - of which Sertraline is the first listed.
NCT01896934 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.
Frequently Asked Questions
What is clinical trial NCT01896934 about?
NCT01896934 is a clinical study titled "Frontal Hypoperfusion Effects on Antidepressant Outcomes in Late-Life Depression". The long-term goal of this line of research is to determine if decreased vascular reactivity and frontal hypoperfusion is associated with poor response antidepressants. Such perfusion deficits could contribute to antidepressant nonresponse as they would hinder improvements in dorsal system metabolis...
What is the current status of trial NCT01896934?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 31 participants. The study started on 2013-07. Estimated completion is 2016-06.
What conditions does trial NCT01896934 study?
This clinical trial studies the following conditions: Major Depressive Disorder.
What interventions are being tested in trial NCT01896934?
The interventions under investigation include: Sertraline (DRUG).
Who is sponsoring clinical trial NCT01896934?
This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01896934 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
RECRUITING · Phase 4
-
A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms
RECRUITING · Phase 4
-
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
RECRUITING · Phase 4
-
Neural Circuit Effects of Ketamine in Depression
RECRUITING · Phase 4
-
Aβ Dynamics in LLMD
RECRUITING · Phase 4
-
Long-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With Depression
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.